N Engl J Med 2016;375:323-34.ArticlePubMed 582
In light of this we had to reevaluate the risk/benefit balance of this intervention: Benefits: immediate benefits are mostly linked to metabolic optimization (I am already metabolically optimized), newer results support metabolic/obesity independent longevity effects especially for reducing dementia risk, but these are very long term with no readily measurable effect
The lack of large, randomized controlled trials makes it unlikely for SUD to become an on-label use anytime soon
Additional crosstalk with other signaling pathways, including MAPK, NF-B, and calcium-dependent mechanisms, facilitates broader anti-inflammatory, anti-apoptotic, and metabolic regulatory outcomes
These nodules presented the biggest drawback to Sculptra and are the main reason that it got a bad name
Diet optimization while on tirzepatide What you eat matters as much as how much you eat